Quince Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$58.1M | -$57.3M | -$34.6M | -$52.0M | -$90.3M |
| Operating expenses | $58.1M | $57.3M | $34.6M | $52.0M | $90.3M |
| Cash from operations | -$41.4M | -$31.9M | -$18.3M | -$44.0M | -$62.9M |
| Capital expenditure | $352,000 | $257,000 | $160,000 | $133,000 | $180,000 |
| Free cash flow | -$41.8M | -$32.2M | -$18.5M | -$44.2M | -$63.1M |
| Impairments | $0 | $0 | $0 | $825,000 | $0 |
| Total assets | $93.5M | $114.5M | $167.9M | $103.9M | $133.2M |
| Total liabilities | $129.2M | $84.3M | $82.8M | $3.3M | $14.6M |
| Total debt | $11.8M | $10.4M | $11.1M | — | — |
Shares outstanding 16.3M · Free float 62.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.